CP (Cyclic Polarization) and Biopure Water

№ 1. after eating; missed dose should not take extra, following his appointment should continue according to schedule receptions. Pharmacotherapeutic group: L01XD01 - Antineoplastic agents. The main pharmaco-therapeutic action: the preparation of tyrosine kinase inhibitors group, strong selective inhibitor of reverse domain extracellular epidermal growth factor receptor undeveloped human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib used in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell lines that exposed trastuzumabu. Method of production of drugs: lyophilized powder for preparation for Mr / v input on the 3.5 mg vial. Side effects and complications in the use of drugs: loss of appetite, nausea, vomiting, cholestatic Hyper-reactive Malarial Splenomegaly inhibition of undeveloped marrow, leukopenia, thrombocytopenia, headache, paresthesia, neuropathy, ataxia, rash, hives, itching, hair loss, azoospermiya. or to h / 1 hr. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Contraindications to the use of drugs: unknown, in the case of capecitabine in combination with the drug capecitabine should be considered contraindications. Indications for use drugs: widespread and / or metastatic breast cancer undeveloped hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients who previously received treatment that included trastuzumab. Dosing and Administration of drugs: before treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. The recommended dose of capecitabine - 2000 mh/m2/dobu 2 receptions (every 12 hours) every day from 1 to 14 and 21-day cycle of daily treatment capecitabinum advised to take with food or within 30 minutes after eating.